Literature DB >> 29208671

CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma.

Hsin-Yu Fang1, Natasha Stephens Münch1, Margret Schottelius2, Jonas Ingermann1, Haibo Liu3, Michael Schauer1, Stefan Stangl4, Gabriele Multhoff4, Katja Steiger5, Carlos Gerngroß6, Moritz Jesinghaus5, Wilko Weichert5, Anja A Kühl7, Antonia R Sepulveda8, Hans-Jürgen Wester2, Timothy C Wang3, Michael Quante9.   

Abstract

Purpose: Barrett's esophagus represents an early stage in carcinogenesis leading to esophageal adenocarcinoma. Considerable evidence supports a major role for chronic inflammation and diverse chemokine pathways in the development of Barrett's esophagus and esophageal adenocarcinoma.Experimental Design: Here we utilized an IL1β transgenic mouse model of Barrett's esophagus and esophageal adenocarcinoma and human patient imaging to analyze the importance of CXCR4-expressing cells during esophageal carcinogenesis.
Results: IL1β overexpression induces chronic esophageal inflammation and recapitulates the progression to Barrett's esophagus and esophageal adenocarcinoma. CXCR4 expression is increased in both epithelial and immune cells during disease progression in pL2-IL1β mice and also elevated in esophageal adenocarcinoma patient biopsy samples. Specific recruitment of CXCR4-positive (CXCR4+) immune cells correlated with dysplasia progression, suggesting that this immune population may be a key contributor to esophageal carcinogenesis. Similarly, with progression to dysplasia, there were increased numbers of CXCR4+ columnar epithelial cells at the squamocolumnar junction (SCJ). These findings were supported by stronger CXCR4-related signal intensity in ex vivo fluorescence imaging and autoradiography with advanced dysplasia. Pilot CXCR4-directed PET/CT imaging studies in patients with esophageal cancer demonstrate the potential utility of CXCR4 imaging for the diagnosis and staging of esophageal cancer.
Conclusion: In conclusion, the recruitment of CXCR4+ immune cells and expansion of CXCR4+ epithelial cells in esophageal dysplasia and cancer highlight the potential of CXCR4 as a biomarker and molecular target for diagnostic imaging of the tumor microenvironment in esophageal adenocarcinoma. Clin Cancer Res; 24(5); 1048-61. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29208671     DOI: 10.1158/1078-0432.CCR-17-1756

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Chemokines and their receptors as biomarkers in esophageal cancer.

Authors:  Masakazu Goto; Mingyao Liu
Journal:  Esophagus       Date:  2019-11-26       Impact factor: 4.230

2.  A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

Authors:  Theresa Osl; Alexander Schmidt; Markus Schwaiger; Margret Schottelius; Hans-Jürgen Wester
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

3.  Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo.

Authors:  Margret Schottelius; Marina Ludescher; Frauke Richter; Tobias G Kapp; Horst Kessler; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2019-08-13       Impact factor: 3.138

4.  Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody.

Authors:  Noboru Oriuchi; Miho Aoki; Naoyuki Ukon; Kohshin Washiyama; Chengbo Tan; Saki Shimoyama; Ken-Ichi Nishijima; Kazuhiro Takahashi; Hiroshi Ito; Takayuki Ikezoe; Songji Zhao
Journal:  Sci Rep       Date:  2020-04-22       Impact factor: 4.379

Review 5.  Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.

Authors:  Ajaz A Bhat; Sabah Nisar; Selma Maacha; Tatiana Correa Carneiro-Lobo; Sabah Akhtar; Kodappully Sivaraman Siveen; Nissar A Wani; Arshi Rizwan; Puneet Bagga; Mayank Singh; Ravinder Reddy; Shahab Uddin; Jean-Charles Grivel; Gyan Chand; Michael P Frenneaux; Mushtaq A Siddiqi; Davide Bedognetti; Wael El-Rifai; Muzafar A Macha; Mohammad Haris
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

6.  Radiolabeled Peptides and Antibodies in Medicine.

Authors:  Paweł Kręcisz; Kamila Czarnecka; Leszek Królicki; Elżbieta Mikiciuk-Olasik; Paweł Szymański
Journal:  Bioconjug Chem       Date:  2020-12-16       Impact factor: 4.774

7.  Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.

Authors:  Philipp Linde; Christian Baues; Simone Wegen; Maike Trommer; Alexander Quaas; Johannes Rosenbrock; Eren Celik; Simone Marnitz; Christiane J Bruns; Thomas Fischer; Klaus Schomaecker; Hans-Juergen Wester; Alexander Drzezga; Lutz van Heek; Carsten Kobe
Journal:  Cancer Imaging       Date:  2021-02-12       Impact factor: 3.909

Review 8.  Stem cells and origins of cancer in the upper gastrointestinal tract.

Authors:  Yoku Hayakawa; Hiroshi Nakagawa; Anil K Rustgi; Jianwen Que; Timothy C Wang
Journal:  Cell Stem Cell       Date:  2021-06-14       Impact factor: 25.269

Review 9.  CXCR4-directed theranostics in oncology and inflammation.

Authors:  Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa
Journal:  Ann Nucl Med       Date:  2018-08-13       Impact factor: 2.668

10.  C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.

Authors:  Kentaro Suzuki; Takashi Ui; Akio Nagano; Akihiro Hino; Yasushi Arano
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.